EPCAM and colorectal cancer: These results further demonstrated that the EpCAM-specific CAR-NK-92 cells could specifically recognize and kill EpCAM-positive colorectal cancer cells and that the CAR-NK-92 cells and regorafenib have synergistic antitumor effects against EpCAM-positive colorectal cancers.